1-4 of 4
Yu Kyeong Hwang
Close
Sort by
Journal Articles

A Pilot Study of MG4101, Allogeneic Natural Killer Cell, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sang A Kim, Youngil Koh, Miyoung Jung, Yu Kyeong Hwang, Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon
Journal: Blood
Blood (2021) 138 (Supplement 1): 3835.
https://doi.org/10.1182/blood-2021-152137
Published: 2021
Journal Articles

A Phase 1 Study of the Combination of MG4101, Ex Vivo -Expanded Allogeneic NK Cells and Rituximab for Relapsed or Refractory Non-Hodgkin Lymphoma

Dok Hyun Yoon, Youngil Koh, Heesook Park, Yu kyeong Hwang, Won Seog Kim
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-133518
Published: 2020
Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell
Journal: Blood
Blood (2019) 134 (Supplement_1): 3801.
https://doi.org/10.1182/blood-2019-128511
Published: 2019
Journal Articles

Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia

Clinical Trials & Observations
Jaewon Choi, Yu Kyeong Hwang, Ki Woong Sung, Soo Hyun Lee, Keon Hee Yoo, Hye Lim Jung, Hong Hoe Koo, Hee-Jin Kim, Hyong Jin Kang, Hee Young Shin, Hyo Seop Ahn
Journal: Blood
Blood (2006) 109 (2): 471–477.
https://doi.org/10.1182/blood-2006-07-032557
Published: 2006